USFDA Concludes InvaGen Facility Inspection With Zero Observations
Cipla said the FDA completed a routine inspection at its InvaGen subsidiary’s New York facility with zero Form 483 observations.
Cipla said the FDA completed a routine inspection at its InvaGen subsidiary’s New York facility with zero Form 483 observations.